4Limonta P,Montagnani MM,Moretti RM.LHRH analogues as anticancer agents:pituitary and extrapituitary sites of action[J].Expert Opin Investig Drugs,2001,10(4):709-720.
5Oefelein MG,Cornum R.Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy:the case for monitoring serum testosterone and a treatment decision algorithm[J].J Urol,2000,164(3 Pt1):726-729.
6Agarwal DK,Costello AJ,Peters J,et al.Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hypertrophy[J].BJU Int,2000,85(6):690-695.
7Eisenberger MA,Blumenstein BA,Crawford ED,et al.Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J].N Engl J Med,1998,339(15):1036-1042.
9Prostate Cancer Trialists' Collaborative Group.Maximum androgen blockade in advanced prostate cancer:an overview of the randomized trials[J].Lancet,2000,355(9214):1491-1498.
10Klotz L,Schellhammer P,Carroll K.A re-assessment of the role of combined androgen blockade for advanced prostate cancer[J].BJU Int,2004,93(9):1177-1182.
5Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publication No. 155. Lyon: IARC, 2002: 745-747.
6Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publication No. 160. Lyon: IARC, 2008.
7Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon.. IARC, 1991.. 101-107.
8Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon.. IARC, 1994: 35-49.
9Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC, 2005: 11-38.
10Felay J. The IARCcrgTools program, http://www, iacr. com. fr/iarccrgtools, htm. IACR. Lyon. 2006.
6DiBlasio CJ.Hammett J,Malcolmal. Prevalence and predic-tive factors for the development of de novo psychiatric illness inpatients receiving androgen deprivation therapy for prostate cancer[J]. Can J Urol,2008,15(5) :4249 - 4256.
7Sotelo MJ. Sex differences in self - concept in Spanish secondaryschool students[J], Psychol Rep, 2000,87(3) : 731 - 734.
8AndrOs E, Eschwege P, Lang H, et al. Metabolic impact of androgen deprivation therapy for prostate cancer[ J]. Prog Uro1,2012,22 ( Suppl 2) : $39-47.
9Whitmore WF Jr. Hormone therapy in prostatic cancer[ J ]. The Ameri- can journal of medicine, 1956,21 (5) :697-713.
10Klotz L, Boceon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix a 12-month camparativer and omized open-label parallel- group phase nl study in patients with prostate cancer [ J]. BJU Int, 2008,102 ( 11 ) : 1531-1538.
